Eli Lilly and Co (MIL:1LLY)
€ 733.1 -11.4 (-1.53%) Market Cap: 703.72 Bil Enterprise Value: 729.10 Bil PE Ratio: 87.15 PB Ratio: 50.94 GF Score: 66/100

Eli Lilly and Co to Discuss World Conference on Lung Cancer Presentation Transcript

Sep 09, 2019 / 05:00PM GMT

Sep 09, 2019 / 05:00PM GMT
Presentation
Sep 09, 2019 / 05:00PM GMT

=====================
Corporate Participants
=====================
* Anne E. White
Eli Lilly and Company - Senior VP & President of Lilly Oncology
* Daniel M. Skovronsky
Eli Lilly and Company - Senior VP & Chief Scientific Officer
* Jacob S. Van Naarden
Loxo Oncology, Inc. - COO
* Kevin Hern
Eli Lilly and Company - VP of IR
* S. Michael Rothenberg
Loxo Oncology, Inc. - VP of Research and Development.

=====================
Conference Call Participants
=====================
* Christopher Thomas Schott
JP Morgan Chase & Co, Research Division - Senior Analyst
* Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research
* Louise Alesandra Chen
Cantor Fitzgerald & Co., Research Division - Senior Research Analyst & MD
* Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot